Global Atrophic Vaginitis Treatment 麻豆原创 Research Report 2023

Publication ID:

PB504230398

Publication Date:

April 12, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Vaginal atrophy (also called atrophic vaginitis) is a condition where the lining of the vagina gets drier and thinner. This results in itching, burning and pain during sex, among other symptoms.听
The global Atrophic Vaginitis Treatment market was valued at US$ 2570 million in 2022 and is anticipated to reach US$ 4403.6 million by 2029, witnessing a CAGR of 8.0% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Atrophic Vaginitis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Atrophic Vaginitis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Atrophic Vaginitis Treatment include Shionogi, Duchesnay, Hormos Medical, Pantarhei Bioscience, Mithra Pharmaceuticals, AMAG Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc, Theramex and Endoceutics, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Atrophic Vaginitis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Atrophic Vaginitis Treatment.
The Atrophic Vaginitis Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Atrophic Vaginitis Treatment market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Atrophic Vaginitis Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Shionogi
Duchesnay
Hormos Medical
Pantarhei Bioscience
Mithra Pharmaceuticals
AMAG Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc
Theramex
Endoceutics
Segment by Type
Vaginal Moisturizers
Water-based Lubricants
Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Atrophic Vaginitis Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Atrophic Vaginitis Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Atrophic Vaginitis Treatment 麻豆原创 Overview
1.1 Product Overview and Scope of Atrophic Vaginitis Treatment
1.2 Atrophic Vaginitis Treatment Segment by Type
1.2.1 Global Atrophic Vaginitis Treatment 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Vaginal Moisturizers
1.2.3 Water-based Lubricants
1.3 Atrophic Vaginitis Treatment Segment by Application
1.3.1 Global Atrophic Vaginitis Treatment 麻豆原创 Value by Application: (2023-2029)
1.3.2 Hospital Pharmacy
1.3.3 Online Pharmacy
1.3.4 Retail Pharmacy
1.4 Global Atrophic Vaginitis Treatment 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Atrophic Vaginitis Treatment Revenue 2018-2029
1.4.2 Global Atrophic Vaginitis Treatment Sales 2018-2029
1.4.3 Global Atrophic Vaginitis Treatment 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Atrophic Vaginitis Treatment 麻豆原创 Competition by Manufacturers
2.1 Global Atrophic Vaginitis Treatment Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Atrophic Vaginitis Treatment Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Atrophic Vaginitis Treatment Average Price by Manufacturers (2018-2023)
2.4 Global Atrophic Vaginitis Treatment Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Atrophic Vaginitis Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Atrophic Vaginitis Treatment, Product Type & Application
2.7 Atrophic Vaginitis Treatment 麻豆原创 Competitive Situation and Trends
2.7.1 Atrophic Vaginitis Treatment 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Atrophic Vaginitis Treatment Players 麻豆原创 Share by Revenue
2.7.3 Global Atrophic Vaginitis Treatment 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Atrophic Vaginitis Treatment Retrospective 麻豆原创 Scenario by Region
3.1 Global Atrophic Vaginitis Treatment 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Atrophic Vaginitis Treatment Global Atrophic Vaginitis Treatment Sales by Region: 2018-2029
3.2.1 Global Atrophic Vaginitis Treatment Sales by Region: 2018-2023
3.2.2 Global Atrophic Vaginitis Treatment Sales by Region: 2024-2029
3.3 Global Atrophic Vaginitis Treatment Global Atrophic Vaginitis Treatment Revenue by Region: 2018-2029
3.3.1 Global Atrophic Vaginitis Treatment Revenue by Region: 2018-2023
3.3.2 Global Atrophic Vaginitis Treatment Revenue by Region: 2024-2029
3.4 North America Atrophic Vaginitis Treatment 麻豆原创 Facts & Figures by Country
3.4.1 North America Atrophic Vaginitis Treatment 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Atrophic Vaginitis Treatment Sales by Country (2018-2029)
3.4.3 North America Atrophic Vaginitis Treatment Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Atrophic Vaginitis Treatment 麻豆原创 Facts & Figures by Country
3.5.1 Europe Atrophic Vaginitis Treatment 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Atrophic Vaginitis Treatment Sales by Country (2018-2029)
3.5.3 Europe Atrophic Vaginitis Treatment Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Atrophic Vaginitis Treatment 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Atrophic Vaginitis Treatment 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Atrophic Vaginitis Treatment Sales by Country (2018-2029)
3.6.3 Asia Pacific Atrophic Vaginitis Treatment Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Atrophic Vaginitis Treatment 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Atrophic Vaginitis Treatment 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Atrophic Vaginitis Treatment Sales by Country (2018-2029)
3.7.3 Latin America Atrophic Vaginitis Treatment Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Atrophic Vaginitis Treatment 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Atrophic Vaginitis Treatment 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Atrophic Vaginitis Treatment Sales by Country (2018-2029)
3.8.3 Middle East and Africa Atrophic Vaginitis Treatment Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Atrophic Vaginitis Treatment Sales by Type (2018-2029)
4.1.1 Global Atrophic Vaginitis Treatment Sales by Type (2018-2023)
4.1.2 Global Atrophic Vaginitis Treatment Sales by Type (2024-2029)
4.1.3 Global Atrophic Vaginitis Treatment Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Atrophic Vaginitis Treatment Revenue by Type (2018-2029)
4.2.1 Global Atrophic Vaginitis Treatment Revenue by Type (2018-2023)
4.2.2 Global Atrophic Vaginitis Treatment Revenue by Type (2024-2029)
4.2.3 Global Atrophic Vaginitis Treatment Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Atrophic Vaginitis Treatment Price by Type (2018-2029)
5 Segment by Application
5.1 Global Atrophic Vaginitis Treatment Sales by Application (2018-2029)
5.1.1 Global Atrophic Vaginitis Treatment Sales by Application (2018-2023)
5.1.2 Global Atrophic Vaginitis Treatment Sales by Application (2024-2029)
5.1.3 Global Atrophic Vaginitis Treatment Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Atrophic Vaginitis Treatment Revenue by Application (2018-2029)
5.2.1 Global Atrophic Vaginitis Treatment Revenue by Application (2018-2023)
5.2.2 Global Atrophic Vaginitis Treatment Revenue by Application (2024-2029)
5.2.3 Global Atrophic Vaginitis Treatment Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Atrophic Vaginitis Treatment Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Shionogi
6.1.1 Shionogi Corporation Information
6.1.2 Shionogi Description and Business Overview
6.1.3 Shionogi Atrophic Vaginitis Treatment Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Shionogi Atrophic Vaginitis Treatment Product Portfolio
6.1.5 Shionogi Recent Developments/Updates
6.2 Duchesnay
6.2.1 Duchesnay Corporation Information
6.2.2 Duchesnay Description and Business Overview
6.2.3 Duchesnay Atrophic Vaginitis Treatment Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Duchesnay Atrophic Vaginitis Treatment Product Portfolio
6.2.5 Duchesnay Recent Developments/Updates
6.3 Hormos Medical
6.3.1 Hormos Medical Corporation Information
6.3.2 Hormos Medical Description and Business Overview
6.3.3 Hormos Medical Atrophic Vaginitis Treatment Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Hormos Medical Atrophic Vaginitis Treatment Product Portfolio
6.3.5 Hormos Medical Recent Developments/Updates
6.4 Pantarhei Bioscience
6.4.1 Pantarhei Bioscience Corporation Information
6.4.2 Pantarhei Bioscience Description and Business Overview
6.4.3 Pantarhei Bioscience Atrophic Vaginitis Treatment Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pantarhei Bioscience Atrophic Vaginitis Treatment Product Portfolio
6.4.5 Pantarhei Bioscience Recent Developments/Updates
6.5 Mithra Pharmaceuticals
6.5.1 Mithra Pharmaceuticals Corporation Information
6.5.2 Mithra Pharmaceuticals Description and Business Overview
6.5.3 Mithra Pharmaceuticals Atrophic Vaginitis Treatment Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Mithra Pharmaceuticals Atrophic Vaginitis Treatment Product Portfolio
6.5.5 Mithra Pharmaceuticals Recent Developments/Updates
6.6 AMAG Pharmaceuticals
6.6.1 AMAG Pharmaceuticals Corporation Information
6.6.2 AMAG Pharmaceuticals Description and Business Overview
6.6.3 AMAG Pharmaceuticals Atrophic Vaginitis Treatment Sales, Revenue and Gross Margin (2018-2023)
6.6.4 AMAG Pharmaceuticals Atrophic Vaginitis Treatment Product Portfolio
6.6.5 AMAG Pharmaceuticals Recent Developments/Updates
6.7 Bayer HealthCare Pharmaceuticals Inc
6.6.1 Bayer HealthCare Pharmaceuticals Inc Corporation Information
6.6.2 Bayer HealthCare Pharmaceuticals Inc Description and Business Overview
6.6.3 Bayer HealthCare Pharmaceuticals Inc Atrophic Vaginitis Treatment Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bayer HealthCare Pharmaceuticals Inc Atrophic Vaginitis Treatment Product Portfolio
6.7.5 Bayer HealthCare Pharmaceuticals Inc Recent Developments/Updates
6.8 Theramex
6.8.1 Theramex Corporation Information
6.8.2 Theramex Description and Business Overview
6.8.3 Theramex Atrophic Vaginitis Treatment Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Theramex Atrophic Vaginitis Treatment Product Portfolio
6.8.5 Theramex Recent Developments/Updates
6.9 Endoceutics
6.9.1 Endoceutics Corporation Information
6.9.2 Endoceutics Description and Business Overview
6.9.3 Endoceutics Atrophic Vaginitis Treatment Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Endoceutics Atrophic Vaginitis Treatment Product Portfolio
6.9.5 Endoceutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Atrophic Vaginitis Treatment Industry Chain Analysis
7.2 Atrophic Vaginitis Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Atrophic Vaginitis Treatment Production Mode & Process
7.4 Atrophic Vaginitis Treatment Sales and 麻豆原创ing
7.4.1 Atrophic Vaginitis Treatment Sales Channels
7.4.2 Atrophic Vaginitis Treatment Distributors
7.5 Atrophic Vaginitis Treatment Customers
8 Atrophic Vaginitis Treatment 麻豆原创 Dynamics
8.1 Atrophic Vaginitis Treatment Industry Trends
8.2 Atrophic Vaginitis Treatment 麻豆原创 Drivers
8.3 Atrophic Vaginitis Treatment 麻豆原创 Challenges
8.4 Atrophic Vaginitis Treatment 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Shionogi
Duchesnay
Hormos Medical
Pantarhei Bioscience
Mithra Pharmaceuticals
AMAG Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc
Theramex
Endoceutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.